The FDA granted breakthrough therapy designation to IMGN632 for treatment of relapsed or refractory blastic plasmacytoid dendritic cell neoplasm, according to the agent’s manufacturer.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
